"Ketamine Could Be The Key To Reversing America’s Rising Suicide Rate" - Cynthia Koons and Robert Langreth
The first ketamine-based drug for suicide prevention could be approved for treatment-resistant depression by March and for suicidal thinking within two years. Allergan Plc is not far behind in developing its own antidepressant that could help suicidal patients. How this happened is one of the most hopeful tales of scientific research in recent memory. Dennis Charney, MD, dean of the Icahn School of Medicine at Mount Sinai and president of academic affairs for the Mount Sinai Health System, works from an office filled with family pictures, diplomas, and awards from a long career in research. One thing on the wall is different from the rest: a patent for the use of a nasal-spray form of ketamine as a treatment for suicidal patients. Dr. Charney has been at the forefront of many studies involving ketamine and is credited with helping widen access to this potentially helpful drug.
— Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, President, Academic Affairs, Mount Sinai Health System